Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 3/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685926 | 1.00 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL17207697 | 0.93 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL3108565 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL3276799 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL1262680 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL25301720 | 0.90 | SYK (0.62) | SYKATMCTSSCTSLCASP1 | |
| SCHEMBL15928906 | 0.90 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL25256638 | 0.90 | SYK (0.62) | SYKATMCTSSCTSLCASP1 | |
| SCHEMBL14119009 | 0.90 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL25318929 | 0.89 | SYK (0.56) | SYKKLK5KLK7ATMPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193904-B1 | DIPEPTIDOMIMETICS AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | UNIV CORNELL (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250114428-A1 | DIPEPTIDOMIMETICS AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | UNIV CORNELL (US) | 2025-04-10 | — | — | US | disclosed |
| US-12016896-B2 | Dipeptidomimetics as inhibitors of human immunoproteasomes | CORNELL UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220411385-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2022-12-29 | — | — | US | disclosed |
| CN-114796207-A | Dipeptide mimetics as inhibitors of human immunoproteasome | 康奈尔大学 | 2022-07-29 | — | — | CN | disclosed |
| US-11384051-B2 | Ionizable compounds and compositions and uses thereof | NITTO DENKO CORPORATION (JP) | 2022-07-12 | — | — | US | disclosed |
| US-20220080022-A1 | DIPEPTIDOMIMETICS AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | UNIV CORNELL (US) | 2022-03-17 | — | — | US | disclosed |
| US-20210340112-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| EP-3313449-B1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| EP-3686184-A2 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170015637-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015637-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-9290515-B2 | Cephem derivative having catechol group | SHIONOGI & CO., LTD (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9290515-B2 | Cephem derivative having catechol group | SHIONOGI & CO., LTD (JP) | 2016-03-22 | — | — | US | disclosed |
| WO-2015163427-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | 田辺三菱製薬株式会社 | 2015-10-29 | — | — | WO | disclosed |
| WO-2015092740-A1 | HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| WO-2004089362-A1 | 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411385-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | SYK 4485/4885KLK5 3017/4885KLK7 4031/4885 |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | SYK 3596/4885KLK5 531/4885KLK7 2445/4885 |
| US-20220080022-A1 | DIPEPTIDOMIMETICS AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | PREP, CTSC, DNPEP | SYK 3047/4885KLK5 612/4885KLK7 992/4885 |
| US-20250114428-A1 | DIPEPTIDOMIMETICS AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | PREP, CTSC, DNPEP | SYK 3047/4885KLK5 612/4885KLK7 992/4885 |
| US-20210340112-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | SYK 4485/4885KLK5 3017/4885KLK7 4031/4885 |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | COMT, CEP170, SLC6A3 | SYK 817/4885KLK5 2516/4885KLK7 3300/4885 |
| US-11384051-B2 | Ionizable compounds and compositions and uses thereof | NCL, CHMP4B, RNASE1 | SYK 3606/4885KLK5 3528/4885KLK7 2341/4885 |
| US-20170015637-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | SYK 4485/4885KLK5 3017/4885KLK7 4031/4885 |
| US-12016896-B2 | Dipeptidomimetics as inhibitors of human immunoproteasomes | PREP, CTSC, DNPEP | SYK 3047/4885KLK5 612/4885KLK7 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.